Compare Amphastar Pharmaceuticals Inc (AMPH) vs Carvana Co (CVNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Carvana Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Carvana Co trades at $71.83 (market cap $81.54B). The key difference: Carvana Co is far larger — about 94.4× Amphastar Pharmaceuticals Inc's market cap, and Carvana Co is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CVNA | |
|---|---|---|
Market Cap | $863.95M | $81.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $95.69 |
52-Week Low | $16.87 | $56.27 |
Enterprise Value | $1.26B | $84.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Carvana (CVNA) trades at $70.85, up 3.73% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, driven by record retail unit growth, though profit margins face pressure. The stock is near its consensus price target of $87.18, with analyst sentiment split between Buy and Hold ratings.
Outlook remains positive due to aggressive scaling and AI-driven cost efficiencies, but risks include high debt levels and competitive threats. Investors should weigh robust growth against valuation concerns, with the current P/E of 37.5 reflecting high expectations. Near-term performance hinges on execution of margin improvement goals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
